Healthcare review
Healthcare business area expects rebound
Our Healthcare business area comprises the Dental, Drug Delivery and Surgery market segments, which produce and market a broad range of products such as dispensers, cartridges, mixers, tips, syringes, pen injectors for subcutaneous delivery of biologicals, and delivery devices for bone repair and tissue treatment. These devices are used in a variety of applications by our end-customers. In the Dental business, our products are used for prosthetics, restoratives, anesthetics and aesthetics. The pen injectors produced and marketed by our Drug Delivery market segment are used in fertility and growth hormone treatments, and to deliver medical substances for the treatment of diabetes, osteoporosis and rare diseases. The delivery devices produced and marketed by our Surgery market segment are used by tissue banks for bone repair and bone cement in trauma surgeries, and by pharma customers with other medical substances for internal and external wound healing.
Key figures Healthcare
January 1 - June 30
|
millions of CHF |
|
2024 |
|
% of HC revenue |
|
+/–% change |
|
+/–% organic 2) |
|
2023 |
|
% of HC revenue |
|
Revenue Dental |
|
54.9 |
|
66.2% |
|
2.4% |
|
3.2% |
|
53.7 |
|
60.2% |
|
Revenue Drug Delivery |
|
21.4 |
|
25.7% |
|
–20.6% |
|
–18.5% |
|
26.9 |
|
30.1% |
|
Revenue Surgery |
|
6.6 |
|
8.0% |
|
–22.8% |
|
–22.8% |
|
8.6 |
|
9.7% |
|
Total revenue Healthcare (HC) 1) |
|
82.9 |
|
100.0% |
|
–7.0% |
|
–5.9% |
|
89.2 |
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business area cost of goods sold |
|
–31.5 |
|
–38.0% |
|
10.1% |
|
|
|
–35.1 |
|
–39.4% |
|
Business area gross profit |
|
51.4 |
|
62.0% |
|
–5.0% |
|
|
|
54.1 |
|
60.6% |
1) Revenue from external customers.
2) Adjusted for acquisition and currency effects.
Revenue by market segment
H1 2024
Revenue by market segment
H1 2023
Positive trends in our Dental market segment
The Dental market segment generated a revenue of CHF 54.9 million, an organic increase of +3.2% compared with the same period last year. The order patterns show strong indications of normalization, and the management is cautiously optimistic to confirm these positive trends in the months ahead.
In the first half of 2024, medmix proudly introduced new dental mixing tips and cartridges certified by the International Sustainability and Carbon Certification (ISCC) Plus. The ISCC is a globally recognized certification system that promotes sustainable, fully traceable, deforestation-free, and climate-friendly supply chains. This independent, multi-stakeholder initiative plays a crucial role in fostering environmentally, socially, and economically sustainable production. As a leader in the dental industry, we are committed to pioneering solutions that not only meet the highest standards of quality but also advance our commitment to environmental responsibility.
Expanding our Drug Delivery market segment pipeline
The Drug Delivery market segment generated a revenue of CHF 21.4 million, which corresponds to an organic decrease of -18.5% year-on-year. This shortfall was largely due to a customer moving a portion of production, as planned, to a second source manufacturer (under license to medmix).
medmix’ project pipeline remains robust, ensuring the delivery of our long-term revenue and profitability targets. We are confident in our ability to introduce significant new projects, such as the PiccoJect autoinjector, the D-Flex injector pen, and other innovative devices. Currently, we are in discussions with a broad spectrum of customers, including major pharmaceutical companies, for a variety of drugs, including GLP-1 and biosimilars.
In a major development this January, we expanded our product portfolio by launching the SicuroJect™ passive needle safety device at Pharmapack Europe in Paris. This device is designed to prevent needle stick injuries for patients, healthcare professionals, and caregivers. In April, our Drug Delivery market segment (“Haselmeier”) announced an exclusive promotion and distribution partnership with NIPRO CORPORATION (“Nipro”) for PiccoJect™ in the Japanese market, enabling market access through Nipro starting from Q1 2025.
Surgery market segment: poised for growth
Revenue in our Surgery market segment was CHF 6.6 million in the first half of 2024, a -22.8% organic decrease compared with the same period last year. The decrease in revenue was primarily driven by an exceptionally strong end to 2023.
In the first half of 2024, medmix successfully completed the ISO 13485 audit for its new facility in Atlanta, USA. This facility is now producing fully validated surgery products, significantly strengthening the company’s presence in the world’s largest healthcare market. In February 2024, medmix participated in the AAOS Congress, demonstrating our commitment to customer engagement and staying abreast of industry trends. We plan to continue this momentum at the forthcoming NASS 2024.